iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil

Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemiaПодробнее

Ibrutinib vs Chlorambucil in CLL - Phase 3 Study BeginsПодробнее

RESONATE-2 follow up: ibrutinib and chlorambucil 5 years onПодробнее

Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLLПодробнее

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve C...Подробнее

Ibrutinib vs chlorambucil in CLL patients not suitable for chemotherapyПодробнее

3-year follow-up of obinutuzumab, ibrutinib and venetoclax for CLLПодробнее

CLL RESONATE-2: Five-year follow-upПодробнее

Dr. Kipps on Ibrutinib Versus Chlorambucil in Treatment-Naïve CLL/SLLПодробнее

Acalabrutinib-obinutuzumab in CLL: 3-year follow-upПодробнее

7-year follow-up of RESONATE-2 trial for CLL/SLLПодробнее

Late-Breaking Abstract: RESONATE 2 Finds First-Line Ibrutinib Superior to Chlorambucil in CLL/SLLПодробнее

3-year follow-up from the TRANSFORM trial: liso-cel is superior to SoC in R/R DLBCLПодробнее

5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclaxПодробнее

Dr. James on Update of Ibrutinib for Chronic Lymphocytic LeukemiaПодробнее

Understanding Chronic Lymphocytic Leukemia with Lindsey Roeker, MDПодробнее

Sequence of administration of ibrutinib with obinutuzumab in R/R CLL patientsПодробнее

4 years of RESONATE data for CLL patients treated with ibrutinibПодробнее

Ibrutinib & chemotherapy (TEDDI-R) in the treatment of secondary CNS lymphomaПодробнее